The primary aim of the clinical trial is to document safety in patients with breast cancer. Another key aim is to investigate the contrast enhancement in MRI of primary and secondary tumors.
”The SpagoPix project is running according to plan and we have taken another step towards the target to offer a cancer selective and gadolinium free contrast agent for MRI of solid tumors”, says CEO Mats Hansen.
The clinical study is named SPAGOPIX01. Study information and updates will be posted at www.clinicaltrials.gov.